On August 1, 2025, a UK Court of Appeal upheld the validity of Moderna’s European Patent No. 3,590,949 (“EP’949”) in a dispute with Pfizer ...

The study tests BNT327, an investigational drug administered via intravenous infusion, in combination with standard chemotherapy drugs like etoposide, carboplatin, paclitaxel, and topotecan. The goal ...

This study could significantly impact BioNTech’s stock performance and investor sentiment, especially if the results demonstrate a breakthrough in breast cancer treatment. The involvement of ...

Federal data shows COVID-19 is trending up in most states, with emergency department visits up among people of all ages.

The expedited approval of mpox vaccines is critical to addressing this public health emergency. Building on the practice in approving COVID-19 vaccines, this analysis investigates the regulatory ...

Parents won't be able to vaccinate healthy children 6 months to 5 years old if the FDA pulls Pfizer's COVID-19 vaccine authorization.

The Food and Drug Administration could pull Pfizer's coronavirus vaccine emergency authorization for children under age 5.

Discover how melanoma vaccines are gaining traction in the clinic and could soon become a treatment option for this deadly ...

GSK and CureVac will together receive $740 million, as well as royalties on sales of COVID-19 vaccines in the US ...

Pfizer (PFE) stock and BioNTech (BNTX) stock in focus as FDA may not renew the authorization for their pediatric COVID shot. Read more here.

The deal helps move BioNTech’s proposed acquisition of CureVac closer to completion. With the settlement, GSK said it will tender the CureVac shares it owns in support of the $1.25 billion acquisition ...

The complex settlement, which hands payouts and royalties to CureVac and partner GSK, comes as BioNTech is inching toward an ...